Sudden suspension of new medicine integration into the finale stage

There is no omen, after the completion of the "triple" of the huge asset reorganization and absorption of mergers, Shanghai Medicine (601607.　　SH) abruptly renewed its suspension on September 7, 2010 and announced that it was planning major issues related to the company. Just one months ago, the new aircraft carrier, a newly-built pharmaceutical industry in Shanghai, has just released its first semi-annual report.　　Shanghai medicine in the announcement of the sudden suspension of the newspaper, was a number of market participants that "should be the last reorganization to do the finishing work."　　Restructuring leave any trail "restructuring time left behind the tail, sooner or later it is to suspend to solve this matter," although it is not possible to determine the exact purpose of Shanghai medicine suspension, but a broker in Shanghai, a pharmaceutical industry analyst tone is still relatively firm.　　The restructuring mentioned by the analyst was the first major medical asset reorganization to be called "the same time in China's capital markets in Hong Kong and Shanghai", which was completed a year ago. October 15, 2009, the real department of the three pharmaceutical companies listed in the reorganization of the integration of the scheme, by the original Shanghai Medicine (600849). SH) absorbed the merger of another two shares listed companies, on the real medicine (600607.　　SH) and Chinese and Western medicine (600842.SH) to complete the return of the city, while on the real Group and medicine group pharmaceutical assets in the restructuring process in the basic realization of the overall listing.　　In fact, careful investors are not difficult to find, after the completion of the merger, the total assets of Shanghai Medicine jumped from 8 billion yuan to 22.3 billion yuan, but after the restructuring, there are still some "slip through the net" outside the listed companies. Shanghai Medicine, released February 2 this year, "Shanghai Medicine exchange for shares absorption merger, in the issue of shares purchase assets and associated transactions report, it was clearly mentioned that" in this major asset reorganization, the Shanghai new Pioneer, Shanghai New Asia and Shanghai Hua Kang and Xinhua Pharmaceutical Co., Ltd. are not included in the scope of the reorganization. "　　"said the anonymity of the securities brokerage analyst, said several of the pharmaceutical group's subsidiaries are likely to be Shanghai medicine this suspension wants to integrate the object." Prior to this, Shanghai Pharmaceutical has completed a series of extension mergers and acquisitions activities, including through acquisitions and capital expansion, merged with Guangzhou Zhongshan Medical and Pharmaceutical Co., Ltd. 51% equity.　　The aforementioned subsidiaries are considered to be the inevitable choice for the subsequent internal integration of Shanghai medicine.　　The report of major assets reorganization indicated that there are many historical problems left in Shanghai new pioneer, Shanghai New Asia and Shanghai Hua Kang ", the company's assets ownership and governance structure need to be adjusted and upgraded, and the production and operation conditions are not stable."　　The Xinhua joint-manufacture pharmaceutical company was punished by the national competent department because of the serious drug damage, which caused the production and operation to be seriously unfavorable, the main preparation production site was revoked the production permit and the operating loss was serious.　　Because of this, the above assets are helpless to stay outside the listed companies, and by the pharmaceutical group for these enterprises to conduct a comprehensive carding and integration. "The integration of medical assets on the real system involves 3 listed companies,It would be wise to leave assets that are not listed on the market, because the assets are large, involve many interests, and can produce a more satisfying restructuring plan than would have been easy, and companies would not want to cause problems with the overall solution because of the flaws in these assets.　　"An investment banker who has had contact with the real system has told this reporter frankly.　　"Antibiotic assets" injected?　　After the merger is completed, the internal integration of Shanghai medicine is still in action.　　March 2 This year, Shanghai Medicine has issued a notice that the company will sell Wanguo stake, Shanghai General Pharmaceutical Co., Ltd. 40% shares, Shanghai International Pharmaceutical Trading Co., Ltd. 40% shares and other assets.　　Shanghai Medical claims to sell two items of pharmaceutical assets, "the general pharmaceutical business is smaller and more fragmented equity structure, and the company's other business sectors of the integration between the limited space", and "international medical trade has no capacity to continue to operate, and there is no integration value." Shanghai new Pioneer, Shanghai New Asia and Shanghai Hua Kang and Xinhua Joint pharmaceutical Companies and Shanghai medicine there is still a huge amount of related transactions, Shanghai pharmaceutical 2010.5 Annual report shows that　　The total number of related transactions with the company amounted to 58.4935 million yuan, which accounted for half of the total associated transactions of the company during the current period and daily operation. That is why, in fact, as early as the major recapitalisation process, Shanghai Pharmaceuticals has made it clear that the unlisted assets will be packaged into Shanghai medicine by the end of 2011.　　At present, the above-mentioned assets are under the management of Shanghai medical trusteeship for regulating related transactions. This reporter learned that Shanghai new pioneer, Shanghai New Asia's main business for the production of antibiotics, Shanghai Hua Kang is mainly engaged in the above two companies sales of products.　　In addition, Xinhua pharmaceutical Factory mainly produces corticosteroids, such as bulk drug products. "These areas are the current business gaps in Shanghai medicine, so the value of injecting the listed companies, but also to increase the company's performance."　　Analysts said that the final injection of antibiotic business will effectively expand the business map of Shanghai pharmaceutical industry. According to China's Securities and pharmaceutical industry analyst Dingdan predicted that the drug group's 09 antibiotic business income of up to 2 billion yuan, which is expected to be integrated into the assets by the end of this year to inject listed companies requirements.　　This is expected to be a full year ahead of the promise of the pharmaceutical group.　　Shanghai Pharmaceutical 2010.5 Annual report shows that the company in addition to antibiotics in the pharmaceutical industry to achieve sales revenue of 4.09 billion yuan, compared with the previous antibiotic assets injected, will make the original pharmaceutical industry in Shanghai pharmaceutical industrial revenue increased by 50%. Interestingly, the antibiotic business is precisely the result of the former Shanghai Group president Wu Jianwen the direct fuse of the Lok Ma.　　According to the medicine group insiders, Wu Jianwen was arrested directly because of the sale of antibiotics drugs in the process of accepting bribes to the total package of sales of foreign transport profits. Before theShanghai medical report on the performance of the Conference, Shanghai Pharmaceutical Chairman Lu Mingfang also confirmed the above news.　　Lu Mingfang admits that it will inject listed companies before the end of the year, and that the actual progress may be "significantly ahead", in the previous restructuring of antibiotics that have not been injected into listed companies.　　One months later, Shanghai Medicine suddenly suspended, combined with the previous position of the company, it is clear that it is easy to be guessed, this suspension may be to complete the aforementioned antibiotic assets injected. On the afternoon of September 7, our correspondent made a call to Shanghai medical Secretary Gegyanqiu, who has been unable to accept this reporter's interview for "in a meeting".